ABVC BioPharma (NASDAQ:ABVC) Announces Earnings Results

ABVC BioPharma (NASDAQ:ABVC) announced its quarterly earnings data on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, FiscalAI reports.

ABVC BioPharma Stock Performance

ABVC stock opened at $1.10 on Wednesday. The company has a market capitalization of $27.98 million, a price-to-earnings ratio of -2.75 and a beta of 0.42. ABVC BioPharma has a fifty-two week low of $0.88 and a fifty-two week high of $5.48. The stock has a fifty day moving average of $1.19 and a 200-day moving average of $1.83.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC bought a new position in shares of ABVC BioPharma during the 3rd quarter worth $48,000. Millennium Management LLC bought a new position in shares of ABVC BioPharma during the 3rd quarter worth $60,000. Finally, Geode Capital Management LLC grew its stake in shares of ABVC BioPharma by 5.8% during the 2nd quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock worth $246,000 after acquiring an additional 6,017 shares during the period. Institutional investors own 11.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.